Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system preparations; generic non-prescription medicines, including food supplements, cosmetics, and medical devices; active substances; biofertilizers; biocides for disinfecting surfaces and hands; and veterinary medicines. Its products are available in the form of sterile injectable powders, capsules, tablets, ointments, gels, creams, pessaries, and suppositories. It offers active pharmaceutical ingredients. The company exports its products to approximately 70 countries. Antibiotice S.A. was founded in 1955 and is headquartered in Iasi, Romania.…
Vallourec sees Q4 EBITDA below expectations as Middle East disruption hits margins
Antibiotice (BVB: ATB) is listed on Bucharest Stock Exchange, where its shares trade in RON. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,354 employees.
The shares were at 1.862 RON on 20 November 2026, down 26.1% over 52 weeks. Its 52-week range is 1.752 RON to 2.590 RON: the price is 28.1% below the high and 6.3% above the low.
At a market capitalisation of 1.25B RON, it trades at 186.2 times trailing earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 660% for ATB. It pays a dividend yielding 1.90% (it pays out 170% of its earnings), against a median of 1.95% among the dividend payers in that peer group.
Antibiotice reports return on equity of 5.6%, an operating margin of 4.3% and revenue down 4.7% year over year.
Its debt exceeds its cash by 350.43M RON, a debt-to-equity ratio of 0.25. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.